The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
AUC(0-24)
C(min)
Early conversion
Kidney transplant
Once daily
Pharmacokinetics
Systemic exposure
Tacrolimus
Trough blood concentration
de novo
Journal
Drug metabolism and pharmacokinetics
ISSN: 1880-0920
Titre abrégé: Drug Metab Pharmacokinet
Pays: England
ID NLM: 101164773
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
25
07
2019
revised:
16
09
2019
accepted:
16
10
2019
pubmed:
16
11
2019
medline:
2
10
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
Available data of early conversion from twice-daily tacrolimus (TAC-BID) to once-daily tacrolimus (TAC-OD) in de novo kidney transplant (KT) recipients are limited. We conducted a prospective study of early conversion to TAC-OD in de novo KT recipients. Eligible patients were enrolled to receive TAC-BID (Prograf®) and then converted to TAC-OD (Advagraf®) by 1:1 ratio, approximately 14 days after KT (range 9-22). Blood samples were investigated for pharmacokinetic parameters before and 7-14 days after the conversion. Fifteen patients were included and provided AUC
Identifiants
pubmed: 31727575
pii: S1347-4367(19)30133-8
doi: 10.1016/j.dmpk.2019.10.004
pii:
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-144Informations de copyright
Copyright © 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no conflict of interest.